MHAA 4549A

Drug Profile

MHAA 4549A

Alternative Names: MHAA-4549A; RG 7745

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Influenza-A virus infections (Monotherapy) in USA (IV) (NCT02623322)
  • 10 Dec 2015 Genentech plans a phase II trial for Influenza-A virus (Monotherapy) in USA (IV) (NCT02623322)
  • 01 Mar 2015 Genentech completes a phase I trial in Influenza A virus infections (In volunteers) in Canada (NCT02284607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top